Biopolymer GmbH & Co.KG - Germany

Slides:



Advertisements
Similar presentations
The Cartridge.
Advertisements

Overview of Stress Urinary Incontinence & Minimally Invasive Slings
Urinary Incontinence Dr. Nedaa Bahkali 2012.
Restylane and Restylane (stylized) are registered trademarks of HA North American Sales AB. © Medicis Aesthetics Holdings Inc. RES04089AR Innovations.
Sling Failures Jerry G. Blaivas, MD Clinical Professor of Urology
Outline the problems that arise from kidney failure and discuss the use of renal dialysis and transplants for the treatment of kidney failure Kidney failure.
Lesson 3 How can you ensure a healthy urinary system? The Urinary System Include healthful sources of fluids to help maintain the function of your urinary.
Lesson 3 How can you ensure a healthy urinary system? The Urinary System Include healthful sources of fluids to help maintain the function of your urinary.
Copyright restrictions may apply Contemporary Review of Injectable Facial Fillers Kontis TC. Contemporary review of injectable facial fillers. JAMA Facial.
Hyaluronic acid filler
Urinary Incontinence Kieron Durkan GPST 1.
Community Continence Program. Kay, 54 Kay, 54 Stopped exercising because she leaks Stopped exercising because she leaks Tired of the odor Tired of the.
TECHNIQUES FOR RETROPUBIC, TRANSOBTURATOR, & SINGLE INCISION SLINGS
What is the place of the Artificial Urinary Sphincter in 2012? Introduction There are an increasing array of surgical options for the treatment of post-prostatectomy.
CAUTI Prevention.
Management of Urinary Incontinence
Stress Urinary Incontinence Dr. Ali Abd El-Monsif Thabet.
Surgical Treatment of Stress Urinary Incontinence
A. Shahrazad MD Shahid Chamran hospital 2011 Iranian continence society.
VesicoUreteral Reflux Biopolymer GmbH & Co.KG - Germany.
Overview of Surgical Management of SUI: Sling Selection, Outcomes, and Adverse Events Eric S. Rovner, M.D. Professor of Urology Medical University of South.
TEMPLATE DESIGN © One Year study evaluating symptomatic relief of patients undergoing trans-obturator tape procedure Dr.
USUHS MSIII Ob/Gyn Clerkship Self Directed Studies Incontinence Ch Academic Year MSIII Ob/Gyn Clerkship Self-Directed Study.
Role of surgery in treatment of fecal incontinence disorders Rasoul Azizi M.D Colo-Rectal Surgeon Associate Professor of surgery School of Medical Sciences,
LALONLALONLALONLALON LALONLALONLALONLALON LALONLALONLALONLALON LALONLALONLALONLALON LALONLALONLALONLALON LALONLALONLALONLALON LALONLALONLALONLALON LA LON.
Stress incontinence surgery in the UK (1). Pre-operative work up and intra-operative complications. Analysis of the BSUG database R.P. Assassa, J. Duckett,
1 THE 3 I’s of UROLOGY Presented by Dr. Mark P. Posner Louisiana Occupational Health Conference August 4, 2012 Baton Rouge, La. 1.
Medication Preparations and Supplies
Introduction The repair of an epithelial wound is merely a normal physiological process. Wound healing depends on elimination of any source of infection.
 Chap 3  J Pistack MS/ED. FATS  Lipids – the true name for fats of all kinds  Lipids include true fats, oils, and the related lipoids and sterols.
CHAPTER11 Wound Healing and the Presence of Biomaterials 11-1 Introduction: Formation of Granulation Tissue 24 hrs: macrophages and inflammatory cells.
Biological Properties ISSUES TO ADDRESS... Biomaterials definition Different types of interaction between body and foreign material What are main characteristics.
 Stephen T Jeffery University of Cape Town, South Africa Urogynaecology and laparoscopy clinic
Chronic Hemodialysis Catheters  In site greater than 3 weeks  Tunneled under the skin  Attached felt cuff  Indicated for acute, chronic hemodialysis,
Abstract Polymeric Porous microspheres are an effective drug delivery mechanism able to control drug release, preventing drug wastage and lowering costs.
How To Design a Clinical Trial
Chapter 27, volumes one and two
Reproductive System PTA 120-Pathology Week 10. Objectives Describe the anatomy, physiology, and functions of the reproductive system. Demonstrate knowledge.
Sculptra. Sculptra is made of poly-L- lactic acid which is a chain of sugar molecules.
Catheterisation small group work
Mini Invasive Vaginal Tape
Dr. BARTANI. Anti-incontinece surgury Retropubic Suspension Surgery for Incontinence in Women Slings.
Introduction 1% to 40% incidence, depending on how incontinence is defined Often resolves within the first postoperative year 95% of men with post-prostatectomy.
YOU CAN DISCOVER YOUR HIDDEN BEAUTY
As published on Vaginal Mesh Lawsuit WebsiteVaginal Mesh Lawsuit Contradistinguishing Urethral Hypermobility and Intrinsic Sphincteric Deficiency.
{ Medical Review Doses and Terminology Part 3.  Intended for applying medication to the skin or mucous membrane  Good for dry skin or areas that need.
Controlling Urine Leakage What You Need To Know David Spellberg MD,FACS Controlling Urine Leakage What You Need To Know David Spellberg MD,FACS.
Val Ward Caroline Grimes Clinical Nurse Specialist: Rochester.
INTERSTIM ® THERAPY for Urinary Control. What are Bladder Control Problems? Broad range of symptoms –May leak small or large amount of urine –May leak.
배뇨장애 II 1. hydronephrosis 2. urinary incontinence Hanjong Park, PhD, RN 1.
Effect of Exercise and self care guidelines on relieving Stress Urinary Incontinence among women in Beni-Suef University Hospital Amal Roshdi A.Mostafa.
SUMMARY & RECOMMENDATIONS for URINARY NCONTINENCE
Pluronic Hydrogel in Post Lumpectomy Breast Reconstruction
How To Design a Clinical Trial
Female Urology & Incontinence in Women
Outline the problems that arise from kidney failure and discuss the use of renal dialysis and transplants for the treatment of kidney failure Kidney failure.
Urine Formation Chapter 15.
Urine Formation Chapter 15.
Buy Restylane Online - Another Anti-Aging Product
BUY RESTYLANEREFYNE ONLINE AND TREAT YOUR NASOLABIAL FOLDS
An Operational Example: The SUI Surgery Module
Emerging Medical Devices for Minimally Invasive Cell Therapy
Chapter-6 : Biomaterials
Portable Biofeedback for Bladder Control
Stress Urinary Incontinence
Initial Office Evaluation
Introduction Urinanalysis.
How can you ensure a healthy urinary system?
Initial Office Evaluation for OAB
Urinary Retention.
Presentation transcript:

Biopolymer GmbH & Co.KG - Germany Urinary Incontinence

Biopolymer GmbH & Co.KG - Germany Treatment Options: Physical Therapy: a conservative early stage treatment for UI , including pelvic floor muscles training known as Kegel exercise. Medications: by means of pharmaceutical drugs ( fesoterodine, tolterodine, oxybutynin, ..etc ). devices: absorbent pads, urinary catheters. Surgical procedures. Bulking agents – Urethral Injections of impant material.

Treatment Options: Surgical procedures: Biopolymer GmbH & Co.KG - Germany Treatment Options: Surgical procedures: TVT: Tension-Free transvaginal sling. TOT: Transoburator tape sling. Mini Sling ( mini-arc ) ( TVT-secure) Marshal-Marchetti-Krantz: retropubic suspension / bladder neck suspension Artificial unrinary sphincter.

Treatment Options: Urethral Injections – Bulking Agents: Biopolymer GmbH & Co.KG - Germany Treatment Options: Urethral Injections – Bulking Agents: Is a minimal surgical procedure providing An alternative in treatment options: The Ideal Bulking agent of choice must include following charecteristics: Biocompatible. Biodegradable. Bio-stable: no deformation after injection. No Migration after implantion. No erosion after implantion. Easy to applicate – without the need to apply pressure when injecting.

Treatment Options: Available Bulking Agents for UI: Biopolymer GmbH & Co.KG - Germany Treatment Options: Available Bulking Agents for UI: Polytetrafluoroethylene(teflon) : no longer used. Autologous fat: no longer used. Macroplastique: silicone elastomer polydimethylsiloxane suspended in polyvinylpyrrolidone PVP Carrier. It is a permanent implant applied by transurethral technique – injection beneath the lining of urethra – can cause urethral erosion with irreversable damage in case of failure of procedure – procedure must be done in operation room. Contigen: Glutar aldehyde cross linked bovine collagen: it begins degradation within 12 weeks with complete degaradation within 19month , and patient must undergo a skin test to exclude hypersinsensitivity due to collagen ( animal origin ) before one month of the procedure.

Biopolymer GmbH & Co.KG - Germany Treatment Options: Available Bulking Agents: 5. Bulkamid: 25% polyacrylamide hydrogel , 97% apyrogenic water, is a permanent implant (nonbiodegradable) 6. Durasphere: carbon coated zirconium oxide particles suspended in water soluble B-glucan vehicle , is a permanent implant, upon clinical trials Durasphere migrates from impantation site which might cause permanent urinary retention. 7. Coaptite: calcium hydroxylapatite particles suspended in sodium carboxymethylcellulose , water, glycerin gel form carrier, upon clinical trials the particles becomes deformed, irregular along with migration from injection site resulting in periurethral fibrosis, obstruction, prolapse.

Biopolymer GmbH & Co.KG - Germany Treatment Options: Available Bulking Agents: 8. Tegress: formrly known as URYX : ethylenevinyl alcohol copolymer suspended in dimethyl sulfoxide: have discontinued sales due to reports of 37% erosion rates. 9. Zuidex: Dextranomere microspheres in cross linked hyaluronic acid carrier. 10.Urodex : DEAE-Sephadex- Dextran positively Charged Dextranomere. Urodex composition: Sodium Hyaluronate cross linked: 17mg DEAE Sephadex Dextran + chagre: 50mg Sodium Chloride: 6.9mg Water for injection: 1.0ml

Urodex designed Technolgy: Biopolymer GmbH & Co.KG - Germany Urodex designed Technolgy: Why to use Urodex ? What is the added Benefits of Urodex ? In order to realize the added benefits of Urodex, a summary explaining the designation technology of the product will answer many questions that may arise. 1. In SUI and as the condition is resulting from pelvic floor muscles weakness that leads to insufficient closure of urethra, basically a material that acts as a bulking agent is needed in order to act in increased tissue thickness at injection site that will aid in complete closure when muscles plays its normal role. and accordingly, the material of choice was DEAE-DEXTRAN ( Diethylaminoethyl- Dextran) , the choice was based upon that Dextran is a Biocompatible , Biodegradable, non-immunogenic molecule. Dextran: consists of linked glucan with side chains attached to the 3-position of the backbone glucose units, and it is produced by bacterial fermentation process ( non- animal origin ).

Urodex designed Technolgy: Biopolymer GmbH & Co.KG - Germany Urodex designed Technolgy: 2. DEAE-Dextran Biomaterial cannot be introduced by injection And as the concept of the products is based upon – minimal Surgical procedure – a carrier material is needed to carry the DEAE-DEXTRAN to site of implantation, the choice of carrier material was the specially designed cross linked hyaluronic acid Technically adjusted to play the role of a ( carrier ), again the choice was upon that HA is a biocompatible, biodegradable, Non-immunogenic molecule. 3. After that and as a long duration effect is favorable in treatment of SUI the Specially designed cross linking process was applied to DEAE-DEXTRAN to obtain a cross Linked DEAE-DEXTRANOMERE or what is called a DEAE-Sephadex-Dextran , Sephadex Is a trade mark for cross linked dextran, where cross linking process results in a long term Duration of the implant to be degraded gradually.

Urodex designed Technolgy: Biopolymer GmbH & Co.KG - Germany Urodex designed Technolgy: 4. Finally, a ( fine tuning ) process was created by Biopolymer GmbH – Germany to ensure maximum effect results outcome for the product ( Urodex ) to be unique and distinguished in SUI Treatment options, the ( fine tuning ) was made by creating a positive charge on DEAE-Sephadex – Dextran which stimulates collagen formation in site of implantation and leading by that for optimum results in treatment of SUI by stimulating tissue regeneration process. Accordingly, DEAE-Sephadex-Dextran is a polycationic cross linked dextran with tissue regeneration stimulating effect. 5. Accordingly, the benefits of Urodex are summarized as following: Biocompatible: as the used materials is a natural component of human body tissues, it is non-immunogenic ( non-animal origin ) , and biocompatibility is optimal due to formation of fibroblast and collagen fibers that surrounds the microparticles. Biodegradable: the used materials are completely degradable with safe clinical profile. Long action duration: due to cross linking process that extends up to 5 five years. No Migration from implant site: due to positively charged microparticles – the positive charge plays a role in ( ancoring ) the implant through inter-cellular interactions leading to fibroblasts and collagen fibers surrounding the implant material as well that microparticles size used ensures no migration. ( safe particel size – 80 micron ). Stimulation of collagen formation: due to positive charges.

Urodex Kit: Urodex Kit: 4 syringes – 1.0ml 2 sterile needles 20G Biopolymer GmbH & Co.KG - Germany Urodex Kit: Urodex Kit: 4 syringes – 1.0ml 2 sterile needles 20G 1 Applicator 1 catheter

Biopolymer GmbH & Co.KG - Germany Urodex Applicator Special design for minimal invasive and safe implantation Controlled implantation in a 4-position (3, 6, 9, 12) symmetrical placement with injection volume of 1.0ml per position. Periurethral Injection technique.

Biopolymer GmbH & Co.KG - Germany Urodex Applicator Designed with measurements for implantation in precise site. After measurement of urethra by catheter , transfer the length to the applicator, insert the applicator into urethra to the previosuly marked measurement and inject the implant material. Video is available for procedure.

URODEX Injection Introduce mounted needle in the applicator Biopolymer GmbH & Co.KG - Germany URODEX Injection Introduce mounted needle in the applicator Important! Opening of the needle in direction upward

The Implantation 1 syringe/1 ml in position 3 Biopolymer GmbH & Co.KG - Germany The Implantation 1 syringe/1 ml in position 3

The Implantation 1 syringe/1 ml in position 9 Biopolymer GmbH & Co.KG - Germany The Implantation 1 syringe/1 ml in position 9

The Implantation 1 syringe/1 ml in position 12 Biopolymer GmbH & Co.KG - Germany The Implantation 1 syringe/1 ml in position 12

The Implantation 1 syringe/1 ml in position 6 Biopolymer GmbH & Co.KG - Germany The Implantation 1 syringe/1 ml in position 6

Biopolymer GmbH & Co.KG - Germany Clinical trials

Biopolymer GmbH & Co.KG - Germany Thank you